Pacira BioSciences (PCRX) News Today

Truist Financial reduced their price target on shares of Pacira BioSciences from $45.00 to $30.00 and set a "buy" rating on the stock in a research report on Thursday.

Pacira BioSciences (NASDAQ:PCRX) will be releasing earnings after the market closes on Tuesday, July 30, Zacks reports.

Clearbridge Investments LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,172,150 shares of the co

Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 3.2%

Pacira BioSciences (NASDAQ:PCRX) Reaches New 12-Month Low at $20.52

Baillie Gifford & Co. lowered its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5.9% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,000,774 shares of the company's stock after selling 62,492 shares duri

Vanguard Group Inc. lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 2.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,098,424 shares of the company

Piper Sandler restated an "overweight" rating and set a $42.00 target price on shares of Pacira BioSciences in a report on Wednesday.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 1,981 call options on the company. This is an increase of approximately 416% compared to the typical daily volume of 384 call options.

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down to $22.74

Barclays lowered shares of Pacira BioSciences from an "overweight" rating to an "equal weight" rating and dropped their target price for the company from $38.00 to $25.00 in a research report on Wednesday.

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have been given a consensus recommendation of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation. The average twelve-month p

HC Wainwright restated a "buy" rating and set a $57.00 target price on shares of Pacira BioSciences in a report on Tuesday.

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) was the target of unusually large options trading on Tuesday. Stock investors bought 5,734 put options on the stock. This is an increase of approximately 1,898% compared to the typical daily volume of 287 put options.

Pacira BioSciences (NASDAQ:PCRX) Sets New 52-Week Low at $21.83

Bridge City Capital LLC acquired a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 61,944 shares of the company's stock, valued at approximately $1,81

Pacira BioSciences (NASDAQ:PCRX) Stock Price Up 4%

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) Director Paul J. Hastings sold 880 shares of the stock in a transaction dated Thursday, June 13th. The stock was sold at an average price of $28.38, for a total transaction of $24,974.40. Following the completion of the transaction, the director now owns 12,724 shares of the company's stock, valued at $361,107.12. The sale was disclosed in a document filed with the SEC, which is available through this link.

Cobalt Capital Management Inc. bought a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 90,000 shares of the company's stock, valued at approximately $3,03

Frontier Capital Management Co. LLC lifted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 15.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,084,542 shares of the company's stock after purchasing an additional 285,

Rubric Capital Management LP lifted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 6.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 491,322 shares of the company's stock after acquiring an additional 31,685

Doma Perpetual Capital Management LLC bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 186,321 shares of the company's stock, val

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been assigned an average rating of "Buy" from the ten analysts that are currently covering the company, MarketBeat reports. Ten equities research analysts have rated the stock with a buy recommendation. The average twelve-month target pr

Norges Bank purchased a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 282,803 shares of the company's stock, valued at ap

Pacira BioSciences (NASDAQ:PCRX) Sees Unusually-High Trading Volume

Stephens Investment Management Group LLC lessened its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,318,005 shares of the company's stock after selling 25,659

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Research analysts at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for Pacira BioSciences in a research report issued on Tuesday, May 28th. Zacks Research analyst R. Department now forecasts that the company will p

Global Alpha Capital Management Ltd. purchased a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7

Hillsdale Investment Management Inc. purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 134,000 s

First Eagle Investment Management LLC lowered its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 50.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 103,081 shares of the comp

National Bank of Canada FI purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,200 shares of the company's stock, valued at approxima

HC Wainwright reiterated a "buy" rating and set a $57.00 price target on shares of Pacira BioSciences in a research report on Wednesday.

Barclays reduced their price target on shares of Pacira BioSciences from $40.00 to $38.00 and set an "overweight" rating for the company in a research report on Wednesday.

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $26.51

Russell Investments Group Ltd. trimmed its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 35.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 226,273 shares of the company's stock